槲皮素(一种天然抗氧化剂)治疗儿童及年轻成人范可尼贫血的1期研究
这项1期剂量探索研究评估了天然抗氧化剂槲皮素在范可尼贫血(FA)患者中的安全性、耐受性和药代动力学。12例患者(中位年龄7岁,范围3-21岁)接受口服槲皮素每日两次共4个月,所有剂量水平耐受良好,确立按体重调整、成人每日最大剂量4000 mg/d为推荐剂量;扩展队列18例用该推荐剂量治疗6个月。部分患者外周血和骨髓干细胞区室的活性氧(ROS)水平降低,分析队列患者达到预设的较基线外周血ROS降低25%的最佳缓解;血小板计数保持稳定至轻度改善(P = .06),中性粒细胞绝对计数(P = .01)和血红蛋白水平逐渐下降(P = .001);基线有骨髓衰竭证据者中15例有8例(53%)在槲皮素治疗后某一时点出现血液学缓解。
要点
- 槲皮素在所有剂量水平耐受良好,推荐剂量为按体重调整、成人每日最大4000 mg/d。
- 部分患者外周血和骨髓干细胞区室ROS水平降低,分析队列达到预设的较基线外周血ROS降低25%的最佳缓解。
- 血小板计数保持稳定至轻度改善(P = .06),中性粒细胞绝对计数(P = .01)和血红蛋白水平逐渐下降(P = .001)。
核心结论
- 槲皮素在范可尼贫血患者中耐受良好,推荐剂量为按体重调整、成人每日最大4000 mg/d。
- 部分患者外周血和骨髓干细胞区室ROS水平降低;血小板计数保持稳定至轻度改善(P = .06),中性粒细胞绝对计数(P = .01)和血红蛋白水平逐渐下降(P = .001)。
- 基线有骨髓衰竭证据者中15例有8例(53%)在槲皮素治疗后某一时点出现血液学缓解。
- 范可尼贫血患者血细胞计数波动常见,限制了对槲皮素影响的准确评估。
研究设计与样本
- 这项1期剂量探索研究纳入12例范可尼贫血患者(中位年龄7岁,范围3-21岁),口服槲皮素每日两次共4个月。
- 扩展队列纳入18例患者,使用推荐的槲皮素剂量治疗6个月。
- 试验注册号为NCT01720147。
主要发现
- 槲皮素在所有剂量水平耐受良好。
- 部分患者外周血和骨髓干细胞区室ROS水平降低。
- 分析队列中接受推荐剂量槲皮素的患者达到预设的较基线外周血ROS降低25%的最佳缓解。
- 血小板计数保持稳定至轻度改善(P = .06),中性粒细胞绝对计数(P = .01)和血红蛋白水平逐渐下降(P = .001)。
- 基线有骨髓衰竭证据者中15例有8例(53%)在槲皮素治疗后某一时点出现血液学缓解。
关键数值与推荐
- 推荐剂量为按体重调整、成人每日最大剂量4000 mg/d。
- 预设的最佳缓解定义为较基线外周血ROS水平降低25%。
- 基线有骨髓衰竭证据者中15例有8例(53%)在槲皮素治疗后某一时点出现血液学缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 范可尼贫血患者血细胞计数波动常见,限制了对槲皮素影响的准确评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fanconi anemia (FA) is a rare inherited disorder characterized by progressive bone marrow failure (BMF) and a predisposition to malignancy. Systemic reactive oxygen species (ROS) and increased sensitivity of FA hematopoietic progenitors to ROS play a key role in the pathogenesis of BMF. Treatment with antioxidants improve hematopoietic function in Fancc-/- mice. We report the safety, tolerability, and pharmacokinetics of quercetin, a naturally occurring antioxidant in the first dose-finding phase 1 study for patients with FA. Twelve patients (median age, 7 years [range, 3-21]) received oral quercetin twice daily for 4 months. Quercetin was well tolerated at all dose levels. Allometrically bodyweight-adjusted dose with a maximum adult daily dose of 4000 mg/d was established as the recommended dose of quercetin. Patients in an expansion cohort (n = 18) were treated using this recommended dose for 6 months. A subset of patients showed reduced ROS levels in the peripheral blood (PB) and bone marrow stem cell compartment. Patients in the analysis cohort treated with the recommended dose of quercetin achieved an a priori-defined optimal response of 25% reduction in the PB ROS level compared with baseline. Platelet counts remained stable to slightly improved over the study period (P = .06). Absolute neutrophil counts (P = .01) and hemoglobin levels gradually declined (P = .001). In those with evidence of BMF at baseline, 8 of 15 patients (53%) had a hematological response at some point after quercetin treatment. Fluctuations in counts are common in patients with FA, limiting accurate assessment of the impact of quercetin use in FA. This trial was registered at www.ClinicalTrials.gov as #NCT01720147.
引用
- Mehta PA, Nelson A, Loveless S, et al. Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia. Blood Adv. 2025. PMID: 39820512. doi:10.1182/bloodadvances.2024015053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。